Bayer/Onyx Kidney Cancer Drug NDA Will Wait For Phase III Results
This article was originally published in The Pink Sheet Daily
Executive Summary
Onyx says the results of the Phase II study for BAY 43-9006 are favorable and support its decision to proceed with its Phase III trial. Its partner, Bayer, previously said the filing could be based on Phase II results.
You may also be interested in...
"Bayer-ly" An Rx Company? Viadur Is Focus Of New Bayer Oncology Unit
Bayer is setting up a new oncology division in West Haven, Conn. as the focus of its U.S. prescription drug business following a Sept. 13 licensing deal with Schering-Plough
Bayer NDA Filing For Renal Cancer Agent May Be Based On Phase II Data
Bayer may submit an NDA for its Raf kinase inhibitor BAY 43-9006 using Phase II data in renal carcinoma, Bayer Health Care Chairman Arthur Higgins said.
Able Unable To Reform On Its Own? Firm Seeks Consent Decree To Address Manufacturing Issues
“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.